1. bookVolume 26 (2018): Issue 3 (July 2018)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Serum hs-CRP, YKL-40 and brain-derived neurotrophic factor (BDNF) associated biomarkers in non-dipper hypertension profile?

Published Online: 31 Jul 2018
Page range: 313 - 324
Received: 10 Feb 2018
Accepted: 04 May 2018
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Background: Twenty-four hours dynamic blood pressure (BP) behaviour displays dipper profile defined as nocturnal systolic BP (SBP) reduction>10% compared to daytime. Non-dipper profile, nocturnal absence of SBP fall, associates an increased cardiovascular risk. We investigated the concomitant association of inflammatory bio-markers - high-sensitivity- C-reactive protein (hs-CRP), Human Chitinase3-like1 (YKL-40) and autonomic nervous system (total brain-derived neurotrophic factor, BDNF) with respect to non-dipping blood pressure status.

Material and method: Using 24h automatic BP measurements, 80 known hypertensive patients were divided into two groups: dipper group included fifty-one dipper patients (age 55.6 ±13.5 years) and non-dipper group consisted of 29 non-dipper subjects (62.07±12.03 years). Serum levels of hs-CRP were evaluated with enhanced immunoturbidimetric assay. Plasma levels of YKL-40 were measured by commercial sandwich ELISA using microplate coated with a monoclonal antibody for CHI3L1. Plasma levels of total BDNF were determined using quantitative sandwich enzyme-linked immunoassay. Statistical analysis of obtained data was performed.

Results: In the non-dipper group, a significant positive association with age over 60 years, hs-CRP values above 1.90 mg/dl was observed along with increased mean values of YKL-40. Non-dipper status is independently and statistically significantly associated with elevated levels of hs-CRP (OR: 3.248, 95% CI: 1.022-10.317, p=0.046) in multivariate odds ratio analysis. No statistically significant positive association between a median total BDNF plasma level of 1430 pg/ml and the non-dipper hypertension profile was identified.

Conclusion: Our study demonstrated that patients over 60 years, in particular, have a higher probability to present a non-dipping pattern of hypertension. hs-CRP and YKL-40 values are more likely to increase in the non-dipping hypertensive patients, and hs-CRP values above 1.9 mg/dl can identify the presence of a non-dipper blood pressure profile.

Keywords

1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017 pii: HYP.0000000000000065.Search in Google Scholar

2. Verdecchia P, Schillaci G, Porcellati C. Dippers versus non-dippers. J Hypertens Suppl. 1991;9(8):S42-4.Search in Google Scholar

3. Karadag B, Ozyigit T, Serindag Z, Ilhan A, Ozben B. Blood pressure profile is associated with microalbuminuria and retinopathy in hypertensive nondiabetic patients. Wien Klin Wochenschr. 2017. DOI: 10.1007/s00508-017-1270-3. (Epub ahead of print). DOI: 10.1007/s00508-017-1270-310.1007/s00508-017-1270-3.(Epubaheadofprint).DOI:10.1007/s00508-017-1270-3Open DOISearch in Google Scholar

4. Tsivgoulis G, Pikilidou M, Katsanos AH, Stamatelopoulos K, Michas F, Lykka A et al. Association of ambulatory blood pressure monitoring parameters with the Framingham Stroke Risk Profile. J Neurol Sci. 2017;380:106-111. DOI: 10.1016/j.jns.2017.07.00710.1016/j.jns.2017.07.00728870547Open DOISearch in Google Scholar

5. Sekizuka H, Osada N, Akashi YJ. The factors affecting the non-dipper pattern in japanese patients with severe obstructive sleep apnea. Intern Med. 2018;57(11):1553-9. DOI: 10.2169/internalmedicine.0029-1710.2169/internalmedicine.0029-17602866529321408Open DOISearch in Google Scholar

6. Cachofeiro V, Miana M, Heras N, Martin-Fernandez B, Ballesteros S, Balfagon G, et al. Inflammation: a link between hypertension and atherosclerosis. Curr Hypertens Rev. 2009;5(1):40-8. DOI: 10.2174/15734020978731433310.2174/157340209787314333Search in Google Scholar

7. Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ et al. – Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling and injury. Ann Rev Physiol. 2011;73:479-501. DOI: 10.1146/annurev-physiol-012110-14225010.1146/annurev-physiol-012110-142250386464321054166Open DOISearch in Google Scholar

8. Rathcke CN, Vestergaard H. YKL-40 – an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61. DOI: 10.1186/1475-2840-8-6110.1186/1475-2840-8-61278905019930630Search in Google Scholar

9. Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, Friis T, et al. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J. 2008;42(5):295–302. DOI: 10.1080/1401743080222056710.1080/1401743080222056718615353Open DOISearch in Google Scholar

10. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J. 2009;30(9):1066–72. DOI: 10.1093/eurheartj/ehp04910.1093/eurheartj/ehp04919270316Search in Google Scholar

11. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S. Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis. 2007;18(5):391–6. DOI: 10.1097/MCA.0b013e328241d99110.1097/MCA.0b013e328241d99117627189Open DOISearch in Google Scholar

12. Henningsen KM, Therkelsen SK, Johansen JS, Bruunsgaard H, Svendsen JH. Plasma YKL-40, a new biomarker for atrial fibrillation? Europace. 2009;11(8):1032–6. DOI: 10.1093/europace/eup10310.1093/europace/eup10319411674Search in Google Scholar

13. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53(2):172-209.Search in Google Scholar

14. Xu T, Zhong C, Wang A, Guo Z, Bu X, Zhou Y, et al. YKL-40 Level and hypertension incidence: a population-based nested. case-control study in China. J Am Heart Assoc. 2016;5(11):e004534. DOI: 10.1161/JAHA.116.00453410.1161/JAHA.116.004534Open DOISearch in Google Scholar

15. Churakova E, Shubina A; Bolotina, M, Masenko V, Karpov Y. New inflammatory marker YKL-40 is associated with early renal function decline in hypertensive patients with concomitant coronary artery disease and type 2 diabetes mellitus. J Hypertens. 2017;35, e-Supplement 2.Search in Google Scholar

16. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framing-ham Offspring Study. Circulation. 2004;110(4):380-5. DOI: 10.1161/01.CIR.0000136581.59584.0E10.1161/01.CIR.0000136581.59584.0Open DOISearch in Google Scholar

17. Shu HS, Tai YY, Chang KT, Chu CY, Hsu PC, Ho-Ming Su, et al. Plasma high-sensitivity C-reactive protein level is associated with impaired estimated glomerular filtration rate in hypertensives. Acta Cardiol Sin 2015;31(2):91-7.Search in Google Scholar

18. Buyukkaya E, Erayman A, Karakas E, Bugra Nacar A, Kurt M, Buyukkaya S, et al – Relation of red cell distribution width with dipper and non-dipper hypertension. Med Glas (Zenica) 2016;13(2):75-81.Search in Google Scholar

19. Pius-Sadowska E, Machaliński B. BDNF - A key player in cardiovascular system. J Mol Cell Cardiol. 2017;110:54-60. DOI: 10.1016/j.yjmcc.2017.07.007. DOI: 10.1016/j.yjmcc.2017.07.00710.1016/j.yjmcc.2017.07.007.DOI:10.1016/j.yjmcc.2017.07.007Open DOISearch in Google Scholar

20. Sherwood A, Steffen PR, Blumenthal JA, Kuhn C, Hinderliter AL. Nighttime blood pressure dipping: the role of the sympathetic nervous system. Am J Hyper-tens. 2002;15 (2 Pt 1):111–8. DOI: 10.1016/S0895-7061(01)02251-810.1016/S0895-7061(01)02251-8Search in Google Scholar

21. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 2013;34(28):2159–219. DOI: 10.1093/eurheartj/eht15110.1093/eurheartj/eht15123771844Open DOISearch in Google Scholar

22. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension. 1994;24(6):793-801. DOI: 10.1161/01.HYP.24.6.79310.1161/01.HYP.24.6.7937995639Open DOISearch in Google Scholar

23. Niiranen TJ, Jula AM, Kantola IM, Reunanen A. Comparison of agreement between clinic and home-measured blood pressure in the Finnish population: the Finn-HOME Study. J Hypertens. 2006;24(8):1549-55. DOI: 10.1097/01.hjh.0000239290.94764.8110.1097/01.hjh.0000239290.94764.8116877957Search in Google Scholar

24. Liu X, Liu C, Schenck H, Yi X, Wang H, Shi x. The risk factors of 9-year follow-up on hypertension in middle-aged people in Tujia-Nationality settlement of China. J Hum Hypertens. 2017;31(12):838-42. DOI: 10.1038/jhh.2017.5810.1038/jhh.2017.58568041428795685Open DOISearch in Google Scholar

25. Habibzadeh F, Habibzadeh P, Yadollahi M. On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem Med (Zagreb). 2016; 26(3): 297–307. DOI: 10.11613/BM.2016.03410.11613/BM.2016.034508221127812299Search in Google Scholar

26. Jimenez MC, Rexrode KM, Kotler G, Everett BM, Glynn RJ, Lee IM et al. Association between markers of inflammation and total stroke by hypertensive status among women. Am J Hypertens. 2016;29(9):1117-24. DOI: 10.1093/ajh/hpw05010.1093/ajh/hpw050497822827235695Open DOISearch in Google Scholar

27. Pierdomenico SD, Pierdomenico AM, Coccina F, Lapenna D, Porreca E. Circadian blood pressure changes and cardiovascular risk in elderly-treated hypertensive patients. Hypertens Res. 2016;39(11):805–11. DOI: 10.1038/hr.2016.7410.1038/hr.2016.74Open DOISearch in Google Scholar

28. Pierdomenico SD, Pierdomenico AM, Di Tommaso R, Coccina F, Di Carlo S, Ettore Porreca E, et al. Morning blood pressure surge, dipping, and risk of coronary events in elderly treated hypertensive patients. Am J Hypertens. 2016;29(1):39-45. DOI: 10.1093/ajh/hpv07410.1093/ajh/hpv074Open DOISearch in Google Scholar

29. Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62(5):397-408. DOI: 10.1016/j.jacc.2013.05.01610.1016/j.jacc.2013.05.016Open DOISearch in Google Scholar

30. Tosu AR, Demir S, Selcuk M, Kaya Y, Akyol A, Ozdemir M, et al. Comparison of inflammatory markers in non-dipper hypertension vs. dipper hypertension and in normotensive individuals: uric acid, C-reactive protein and red blood cell distribution width readings. Postepy Kardiol Interwencyjnej. 2014;10(2): 98–103. DOI: 10.5114/pwki.2014.4351410.5114/pwki.2014.43514Open DOISearch in Google Scholar

31. Bakirci EM, Degirmenci H, Hamur H, Gunay M, Gulhan B, Aydin M, et al. – New inflammatory markers for prediction of non-dipper blood pressure pattern in patients with essential hypertension: Serum YKL-40/Chitinase 3-like protein 1 levels and echocardiographic epicardial adipose tissue thickness. Clin Exp Hypertens. 2015;37(6):505-10. DOI: 10.3109/10641963.2015.101312210.3109/10641963.2015.1013122Search in Google Scholar

32. Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res. 2006;55(6):221-7. DOI: 10.1007/s00011-006-0076-y10.1007/s00011-006-0076-yOpen DOISearch in Google Scholar

33. Vermehren-Schmaedick A, Jenkins VK, Hsieh HY, Brown AL, Page MP, Brooks VL, et al. Upregulation of brain-derived neurotrophic factor expression in no-dose ganglia and the lower brainstem of hypertensive rats. J Neurosci Res 2013;91(2):220–9. DOI: 10.1002/jnr.2315810.1002/jnr.23158Open DOISearch in Google Scholar

34. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett. 2002;328(3): 261–4. DOI: 10.1016/S0304-3940(02)00529-310.1016/S0304-3940(02)00529-3Open DOISearch in Google Scholar

35. Hojo Y, Noma S, Ohki T, Nakajima H, Satoh Y. Autonomic nervous system activity in essential hypertension: a comparison between dippers and non-dippers. J Hum Hypertens. 1997;11:665–71. DOI: 10.1038/sj.jhh.100051510.1038/sj.jhh.1000515Open DOISearch in Google Scholar

36. Sherwood A, Steffen PR, Blumenthal JA, Kuhn C, Hinderliter AL. Nighttime blood pressure dipping: the role of the sympathetic nervous system. Am J Hyper-tens. 2002;15(2 Pt1): 111–8. DOI: 10.1016/S0895-7061(01)02251-810.1016/S0895-7061(01)02251-8Search in Google Scholar

37. Kasselman LJ, Sideris A, Bruno C, Perez WR, Cai N, Nicoletti JN, et al. BDNF: a missing link between sympathetic dysfunction and inflammatory disease? J Neuroimmunol. 2006;175(1-2):118-27. DOI: 10.1016/j.jneuroim.2006.03.00810.1016/j.jneuroim.2006.03.00816631934Open DOISearch in Google Scholar

38. Kadoya M, Koyama H, Kanzaki A, Kurajoh M, Hatayama M, Shiraishi J, et al. Plasma brain-derived neurotrophic factor and reverse dipping pattern of nocturnal blood pressure in patients with cardiovascular risk factors. PLoS One. 2014;9(8):e105977. DOI: 10.1371/journal.pone.010597710.1371/journal.pone.0105977414331625153796Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo